Objective Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently approved antihyperglycemic medications. We sought to describe their association with euglycemic diabetic ...

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher ...

Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...

Type 2 diabetes is a global health challenge affecting more than 400 million adults. While it is often seen as a lifelong ...

MONDAY, March 3, 2025 (HealthDay News) -- Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) ...

SGLT-2 inhibitors, compared with DPP-4 inhibitors, were associated with a lower risk for liver cirrhosis among patients with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors ...

The risk for moderate or severe COPD exacerbation was lower among those treated with SGLT-2is and with GLP-1 RAs versus DPP-4is.

Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.

The biggest advantage of the drug going off patent is that the prices will plummet. The patented medicine, sold as Jardiance, ...

Depression risk for patients receiving GLP-1 RA was slightly higher than those receiving SGLT-2i and lower than those receiving DPP-4i.

Researchers found that the rate difference of depression was 3.48 per 1000 person-years between GLP-1 RA users and SGLT-2i users. HealthDay News — For older adults with type 2 diabetes (T2D ...

The first cohort included 36,082 GLP-1 receptor agonist users and 234,028 DPP-4 inhibitor users, and the second cohort included 32,336 GLP-1 receptor agonist users and 96,212 SGLT-2 inhibitor users.